BURLINGTON, Mass.–(BUSINESS WIRE)–Please replace the release dated January 6, 2025, with the following corrected version due to multiple revisions. The updated release reads: PHARMAESSENTIA ANNOUNCES POSITIVE TOPLINE PHASE 3 DATA FROM SURPASS-ET STUDY EVALUATING ROPEGINTERFERON ALFA-2B-NJFT (P1101) FOR ESSENTIAL THROMBOCYTHEMIA SURPASS-ET trial achieved its primary endpoint, demonstrating a durable response in 42.9% of participants in the P1101 group versus 6.0% in the comparator group (p=0.0